71 results
SC 14D9/A
EX-99
CBAY
Cymabay Therapeutics Inc
28 Feb 24
Tender offer solicitation (amended)
5:01pm
), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced … biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need. Our deep
SC TO-T
EX-99
CBAY
Cymabay Therapeutics Inc
23 Feb 24
Third party tender offer statement
6:09am
focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need. The Company’s deep understanding
SC14D9C
EX-99.2
CBAY
Cymabay Therapeutics Inc
12 Feb 24
Written communication relating to third party tender offer
5:29pm
, this achievement recognizes the value that seladelpar will certaimly bring to those patients with primary biliary cholangitis or PBC. PBC is a rarer chronic
SC TO-C
EX-99.3
CBAY
Cymabay Therapeutics Inc
12 Feb 24
Information about tender offer
4:14pm
rating scale (NRS).
PBC is a rare, chronic, cholestatic liver disease mainly affecting women (1 in 1,000 women over the age of 40, or about 130,000 total … , chronic, cholestatic liver disease mainly affecting women (1 in 1,000 women over the age of 40 or about 130,000 total people in the U.S
SC TO-C
EX-99.2
d12jsqp8 1p7rj3r
12 Feb 24
Information about tender offer
4:14pm
8-K
EX-99.1
h1ckrg4bjf7 8o
12 Feb 24
Entry into a Material Definitive Agreement
8:42am
SC TO-C
EX-99.1
icxr 8mck
12 Feb 24
Information about tender offer
8:39am
424B5
9czpdbb5
12 Sep 23
Prospectus supplement for primary offering
4:02pm
424B5
mprvzmeag2kh30jmpyty
11 Sep 23
Prospectus supplement for primary offering
6:19am
S-3ASR
5fbez
23 Jun 23
Automatic shelf registration
4:48pm
424B5
8j4b2gfsm dwf7u
18 Nov 21
Prospectus supplement for primary offering
5:11pm
424B5
q5ocfx11
17 Nov 21
Prospectus supplement for primary offering
4:45pm